Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists

(2021) Lisa Gill et al.   JOURNAL OF WOMENS HEALTH

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obesity in adults: a clinical practice guideline

(2020) Sean Wharton et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Switching between GLP‐1 receptor agonists in clinical practice: expert consensus and practical guidance

(2020) Akshay B Jain et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

(2019) Richard Pratley et al.   LANCET

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

(2019) Thomas R Pieber et al.   Lancet Diabetes & Endocrinology

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

(2019) Michael A Nauck et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

(2018) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

(2017) Mirko Sikirica et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

GLP-1 and weight loss: unraveling the diverse neural circuitry

(2016) Scott E. Kanoski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

(2016) W. Timothy Garvey et al.   Endocrine Practice

Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study

(2015) Jean-Francois Gautier et al.   ADVANCES IN THERAPY

The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.

(2015) Sony S. Thazhath et al.   DIABETES

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Guidelines for Obesity Management in Adults

(2015) Volkan Yumuk et al.   Obesity Facts